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ABSTRACT
Intracranial Hypertension is a neurological condition secondary to raised intracranial pressure in the absence of
identifiable intracranial pathology and with normal cerebrospinal fluid composition. It can be a challenging condition to
manage. One of the treatment modalities, optic nerve sheath fenestration is an important, yet under utilized mode of
treatment, particularly in patients with visual symptoms.
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INTRODUCTION:

and George4 reported headache in 94% of their
patients, transient visual obscurations in 68%,
intracranial noise in 58%, photopsia in 54% and
retrobulbar pain in 44% of patients. Papilledema is
considered to be the cardinal sign of IIH. In the absence
of papilledema, obesity and pulsatile tinnitus can
suggest high CSF pressure in a patient with chronic
headaches. Wall and George4 also reported impairment
of visual acuity in 13% of their patients’ initial visits and
of visual field abnormality in 90% of their patients on
perimetry. Typical visual field defects were blind spot
enlargement, nasal defect, arcuate scotoma and
generalized field constriction.

Intracranial Hypertension (IIH) is a neurological disorder
characterized by raised cerebrospinal fluid pressure
without identifiable intracranial pathology and with
normal cerebrospinal fluid (CSF) composition.1 This
condition usually affects overweight women of
childbearing age but can affect either gender at any
age. The incidence is 0.9-2.2 per 100,000 in the
general population rising to 19.3-21.3 per 100,000 in
obese women of childbearing age.1
PATHOGENESIS:
The pathogenesis is unclear. Various factors including
obesity, sex hormone, prothombotic factors and altered
CSF dynamics have been suggested for the same.2
Obesity has long been associated with IIH. In a
prospective study of 34 patients with IIH, Rowe3
showed 94% of their patients to be overweight (BMI
>26kg/m2) and 73% obese (BMI >30 kg/m2). Obese
females between the ages 16-24 were 17 times more
likely to develop IIH than their age-matched controls.3

Friedman5 described an updated criterion for
diagnosing IIH (Table 1). The diagnosis of IIH requires
presence of papilledema (Table 2 and 3), appropriate
brain imaging to exclude intracranial abnormalities and
a lumbar puncture to document raised intracranial
pressure (>25cm H2O) and normal CSF constituents.5
Magnetic resonance imaging (MRI) is considered better
than a computed tomography (CT) scan, however, in
atypical cases magnetic resonance venography (MRV)
along with MRI may be required. MRI may reveal signs
of empty sella turcica, flattening of posterior globe and
buckling of optic nerve. Ventricular size should be
normal for the patient’s age, however slit-like ventricle
may be seen in IIH.6

PRESENTATION:
Patients with IIH can present with visual and non-visual
symptoms. In a prospective study of 50 patients, Wall
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IIH is a diagnosis of exclusion and conditions mimicking
IIH should be excluded (Table 4). Various conditions are
associated with IIH and need to be considered in the
workup of the patient (Table 5)7. Bababeyge described
two non-obese patients on minocycline who developed
visual loss secondary to papilledema.8

Table 4: Differential Diagnosis
Important differential diagnosis of Idiopathic intracranial hypertension
Dural venous sinus thrombosis
Hypertensive retinopathy
Optic disc anomalies (disc drusen and tilted optic disc)
Intracranial hypertension due to medication or a disease

Table 1. Modified Criteria for Diagnosis IIH [Friedman &
Jacobson]

Table 5: List of systemic diseases and medications
associated with intracranial hypertension

Criteria for diagnosing idiopathic intracranial hypertension

Systemic diseases and medications associated with intracranial

• Symptoms, if present, are only those of generalized intracranial hypertension or

hypertension

papilledema

Medication

• Signs, if present, are only those of generalized intracranial hypertension or
papilledema
• Elevated CSF pressure demonstrated on lumbar puncture in the lateral
decubitus position
• Normal CSF constituents
• No evidence of space occupying lesion or venous sinus thrombosis on imaging

Systemic disease

Tetracycline

Systemic Lupus Erythematosis

Minocycline

Behcet’s disease

Doxycycline

Polycystic ovarian disease

Steroids

Hypothyroidism

Steroid withdrawal

• No other explanation for the raised CSF pressure

Vitamin A

TREATMENT:

Table 2: Feature of papilledema

Treatment of IIH includes weight reduction, medical
management, elimination of associated factors, serial
lumbar puncture and surgical intervention

Features of papilledema
• Peripapillary nerve fiber layer edema obscuring the retinal blood vessels
• Absent spontaneous venous pulsations
• Distended retinal veins

NON-SURGICAL TREATMENT

• Peripapillary haemorrhages and exudates
• Peripapillary retinal or choroidal folds
• Nerve fiber layer infarcts

Johnson9 observed that at least 6% of weight loss could
result in reduction of ICP with accompanying resolution
of papilledema and visual field dysfunction. Surgically
induced weight loss has shown similar results.7

Table 3: Grading of papilledema
Stage
0

The mainstay of IIH medical management is
acetazolamide, a carbonic anhydrase inhibitor that
reduces CSF production by decreasing sodium ion
transport across the choroidal epithelium. The starting
dose is 250 mg twice daily to ensure tolerance,
increasing to a maintenance dose of 1-2 g per day.
Patients intolerant to acetazolamide can be treated
with furosemide (loop diuretic) an ACE inhibitor or
topiramate an anti-convulsion drug. IIH symptoms may
resolve after lumbar puncture.7

Description
Normal optic disc. Radial nerve fiber layers without nerve fiber
layertortuosity. Blurring of nasal, superior, inferior margins
inversely proportional to disc size. Greater the size, less the
blurring.

1

C-shaped halo. Normal temporal margin. Concentric or radial
retrochoroidal folds.

2

Circumferential halo. Nasal border elevation.

3

Obscuration of one or more segment of a major blood vessel.

4

Total obscuration on the disc of a segment of a major blood

SURGICAL TREATMENT

vessel. Elevation of the entire nerve head, including the cup.
5

The surgical options are optic nerve sheath fenestration
(ONSF) or CSF diversion procedures such as
lumboperitoneal shunt (LPS) or ventriculoperitoneal
shunts (VPS).

Partial obscuration of all the blood vessels on the optic disc and
total obscuration of at least one major blood vessel. Dome shape
protrusion, representing anterior expansion of the optic nerve
head.

Optic nerve sheath fenestration (ONSF) was first
described by DeWecker 10 to allow the flow of CSF from
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contralateral eye continued improving with greatest
effect seen 12 months post ONSF, corresponding with
improvement in the visual function.

the sub-arachnoid space to the orbital space. Almost a
century later, in 1964, Hayreh 11 refined the technique
of ONSF that resulted in the resolution of papilledema.
This led to the theory that ONSF could be the preferred
surgical option when headache is not the predominant
symptom.12 CSF shunting is considered to be the
procedure of choice when headache is the
predominant symptom.13 However, studies have shown
significant reduction of the symptoms of headache
after ONSF, which may suggest the role of ONSF as an
alternative, for patients with headaches as the
predominant symptom.14

In general, ONSF is an effective long‐term procedure for
visual loss associated with IIH. Multiple studies have
reported that majority of complication are often
transient and resolve without long-term effects.
ONSF is considered to be the better option in patients
with visual loss in IIH, while CSF shunting is the
favorable option in patients with refractory headache.
The two commonly performed CSF shunting
procedures, ventricular peritoneal shunt (VPS) and
Lumboperitoneal shunt (LPS), are considered to be
almost similar in their outcome. Tarnaris et al20, in a
retrospective review of 34 patients with 63 shunts
found no significant difference in visual outcome or
headache between the two groups; VPS and LPS,
however, headache improved more than visual
disturbance for both the groups. The study also
reported 20.5% of the patients had shunt procedure
related complication with 35% requiring shunt revision.
Abubaker 12 similarly found better outcomes with
headache compared to visual disturbance post CSF
shunting procedure and also noted LPS to have lower
failure rate but higher revision rate. El-Saadany21, in the
retrospective review of 22 patients, found patients
showed improvement in both headache (19/22) and
papilledema (16/22). Moreover, the study reported 9%
shunt infection rate, 27% shunt obstruction and 13%
shunt over drainage. A 10-year retrospective review of
53 patients by Sinclair 22 found an overall improvement
in the visual symptoms post-shunting but noted
headache persisted in 79% of post-LPS patients. The
review also noted a high rate of shunt complications,
shunt revisions, and persistent post-shunt headache.
Karabatsou23 et al retrospectively reviewed 21 post LPS
patients. The study highlighted7 shunt related
infections, 7 tonsillar herniations, 17 shunt migrations
with 18 out of 22 patients requiring a total of 63 shunt
revision procedures.

Banta and Ferris 15 described the effectiveness of ONSF
in a case series involving 158 eyes by demonstrating
improvement in the visual acuity of 94% of the eyes
post surgery. In addition, 88% showed stabilization or
improvement in the visual field. One eye suffered
visually significant complication. The study reported
less favorable outcome for the symptoms of headache.
In this study, 61 patients presented with headache and
only 31% reported improvement in their headache post
ONSF.
A study by Chandrasekaran et al16, on 51 eyes of 32
patients demonstrated that patients with mild visual
field defect improved or stabilized post ONSF, while
patients with severe visual field defect were found to
stabilize post ONSF. Also younger patients showed
more favorable result in this study. In the study it was
found overall complication rate of 15.6%; all being
self-limiting, three patients had diplopia, two had
anisocoria and one had disc hemorrhage. All
procedures were approached by medial subconjunctival
approach and performed by the same surgeon. Plotnik
and Kosmorsky17 reported a complication rate of 40%,
which included temporary motility disorder (29%),
pupillary dysfunction (11%) and vascular complication
(11%): comprising of two central retinal artery
occlusion, one transient outer retinal ischemia and one
superotemporal branch retinal artery occlusion.
Sergott18 studied the benefit of ONSF in patients with
prior LPS placement. The study enrolled 23 patients
with previous multiple LPS; visual improvement was
demonstrated in six patients after ONSF. This suggested
that despite functional CSF shunt, ONSF could be
beneficial in patients with progressive visual
deterioration, or in the event of failure of the shunt.

SURGICAL TECHNIQUE OF ONSF
Although many techniques have been described in
literature, the preferred method for the author is lid
crease approach. Other commonly used methods for
access to the nerve are via medial orbitotomy and
lateral orbitotomy.

In a retrospective review of 62 eyes by Alsuhaibani et
al19 found an additional benefit of unilateral ONSF to
reduce the disc swelling in the contralateral
un-operated eye. The reduced disc swelling in the
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the optic nerve sheath is fenestrated to release the
fluid. There is a risk of ocular muscle palsy with this
surgery. Lateral orbitotomy approach involves skin
incision, removal of the lateral orbital wall, giving a wide
access to the optic nerve. However, it is a longer
surgical procedure with a possible risk of damage to the
ciliary body. The lid crease approach is gaining favor, as
it does not involve bone removal or muscle detachment
but the learning curve is considerably higher in this
approach.13

8.

9.

SOCIETAL IMPACT OF IDIOPATHIC INTRACRANIAL
HYPERTENSION:

10.

The societal impact of this condition is high and often
goes unrecognized. According to the intracranial
hypertension registry in the USA, in 2007 the total cost
of IIH was estimated to be 444 million USD, of which
232 million USD is attributable to direct medical and
surgical expense.24

11.
12.

CONCLUSION

13.

IIH can cause visual loss. Medical management is the
first line of treatment in IIH. In refractory cases and in
patients presenting with visual loss, optic nerve sheath
fenestration is an important and viable treatment
option to prevent sight loss in this challenging
neuro-ophthalmological condition.

14.
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